Target-Driven lncRNA Discovery Tools
Explore our specialized genomics products optimized for characterising non-coding transcripts and accelerating downstream multi-omics pipelines.
DNBSEQ Pre-made Libraries for lncRNA Discovery
Cost-efficient, high-fidelity library preparations structured to streamline large-scale transcriptomic screening campaigns.
Learn More →
circ-RNA & lncRNA Multi-Omics Profiling
Advanced profiling protocols designed to map circular and long non-coding RNA networks with single-nucleotide precision.
Learn More →
TGuide Smart Soil / Stool RNA & DNA Kit
Automated extraction kits optimized for complex environmental and microbiome samples, preserving fragile non-coding RNA structures.
Learn More →
Bioinformatic Toolkits for non-coding RNA
Preconfigured analytical pipelines designed to fast-track the identification, annotation, and target prediction of novel transcript structures.
Learn More →Commercial & Industrial Landscape of lncRNA Sequencing
Unlocking the regulatory dark matter of the genome to build next-generation diagnostic and therapeutic assets.
Over the past decade, the biological paradigm has undergone a seismic shift. Once dismissed as "evolutionary noise" or genomic "dark matter," non-coding RNAs—specifically Long Non-Coding RNAs (lncRNAs)—have emerged as key orchestrators of cellular complexity. Spanning transcripts longer than 200 nucleotides that do not translate into functional proteins, lncRNAs regulate gene expression at transcriptional, post-transcriptional, and epigenetic levels. Today, Long Non-Coding RNA Sequencing (lncRNA-Seq) is rapidly becoming a cornerstone of industrial biotechnology, pharmaceutical development, and clinical translational research.
From a commercial perspective, the market positioning of lncRNA-Seq has evolved from basic academic discovery to targeted clinical and industrial product lines. Biopharma companies leverage lncRNA expression profiles to discover novel biomarkers for oncology, immunology, and neurodegenerative disorders. Because lncRNAs exhibit highly tissue- and stage-specific expression patterns compared to protein-coding mRNAs, they serve as exceptionally precise diagnostic tools, enabling developers to design highly specific liquid biopsy panels and companion diagnostics.
Market Projections & Positioning
The global multi-omics market is growing at a compound annual growth rate (CAGR) of over 12%. Within this space, non-coding RNA analysis is expanding rapidly due to its utility in therapeutic targeting (e.g., RNA therapeutics, antisense oligonucleotides, and CRISPR-based gene editing validation). Integrating lncRNA-Seq into standard multi-omics pipelines provides a competitive advantage for service providers and drug developers alike.
Emerging Development Trends in lncRNA Diagnostics and Therapeutics
The translation of lncRNA biology into commercial pipelines is driven by several technological and methodology-driven trends:
- RNA-Targeted Therapeutics: The approval of antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) has opened the door for targeting disease-associated lncRNAs directly. High-throughput lncRNA-Seq is essential for identifying targetable transcripts and evaluating off-target effects across the entire transcriptome.
- Single-Cell and Spatial Resolution: Bulk RNA-Seq can mask the cell-type-specific nature of lncRNA regulation. Incorporating single-cell lncRNA-Seq and spatial transcriptomics enables researchers to map long non-coding transcripts within their native tissue microenvironments, revealing critical spatial patterns in tumors and developing organs.
- Integration with Epitranscriptomics: Investigating modifications like m6A, m5C, and pseudouridylation on lncRNAs is a growing trend. Combining sequencing protocols with modification-specific enrichment techniques provides a deeper layer of product positioning for researchers aiming to catalog the functional states of non-coding molecules.
Biomarker Technologies (BMKGene)
Empowering global research networks with cutting-edge multi-omics platforms and automated molecular workflows.
Biomarker Technologies (BMKGene), founded in 2009, is a leading genomics service provider with over 16 years of continuous innovation in high-throughput sequencing and bioinformatics. Backed by more than 60 national invention patents and 200+ software copyrights, we deliver comprehensive multi-omics solutions—spanning genomics, metagenomics, epigenetics, single-cell omics, transcriptomics, and our proprietary BMKMANU S3000 spatial transcriptome technology—supported by our advanced BMKCloud bioinformatics platform. We have established long-term collaborations with organizations across 84 regions worldwide, providing reliable genomic solutions on a global scale.
Our Sequencing & Analytical Platforms
Long-Read Sequencing
PacBio Platforms: Sequel II, Sequel, RSII
Nanopore Platforms: PromethION P48, GridION X5, MinION
Short-Read & Single-Cell
Illumina Platforms: NovaSeq
BGI-Sequencing: DNBSEQ-G400, DNBSEQ-T7
10X Genomics: 10X ChromiumX, 10X Chromium Controller
Optical Mapping & Mass Spec
Bionano Irys System for structural variation mapping.
Waters XEVO G2-XS QTOF & QTRAP 6500+ for advanced proteomics and metabolomics.
Over 20,000 Square Feet Facility
Our infrastructure houses advanced biomolecular laboratory instruments designed to maintain strict quality control parameters. The facility features dedicated zones for sample extraction, library construction, clean rooms, and sequencing operations. Every step, from sample receipt to raw data delivery, is governed by rigorous Standard Operating Procedures (SOPs) to ensure maximum technical reproducibility.
Reliable, Easy-to-use On-line Bioinformatic Analysis Platform
The self-developed BMKCloud platform represents the digital backbone of our analytics services. Equipped with CPUs featuring 41,104 memory units and 3 PB of total storage, the infrastructure integrates 4,260 computing cores, delivering a peak computing power exceeding 121,708.8 Gflop per second. This allows researchers to perform complex lncRNA-Seq alignment, novel transcript prediction, target gene network construction, and multi-omics integration in a secure, web-based environment.
Fully Automated NGS Library Construction
Minimizing human error and scaling throughput through robotic automation.
Brilliant Lab 1000 (BL1000)
Biomarker Technologies (BMKGene) and PerkinElmer have jointly built a fully automated experimental production line, called Brilliant Lab 1000 (BL1000), which is applied to high-throughput NGS library construction services.
BMKGENE strives to greatly improve the entire line of sequencing products in terms of product types, production line throughput, delivery quality, and cycle time, to provide customers with better sequencing services.
Inside Our Automated Facilities
Deep Application Scenarios of lncRNA Sequencing
Translating basic non-coding biology into clinical diagnostics, agriculture, and complex disease models.
1. Oncology & Liquid Biopsy Development
In cancer biology, lncRNAs act as oncogenes or tumor suppressors. Because they are frequently packaged into exosomes and released into bodily fluids, they represent highly stable biomarkers for non-invasive liquid biopsies. High-throughput lncRNA-Seq allows developers to identify tumor-associated exosomal lncRNAs. For instance, lncRNAs like PCA3 have been successfully translated into clinical diagnostic assays for prostate cancer. By positioning lncRNA-Seq as a primary discovery tool, diagnostic companies can identify novel panels that distinguish early-stage malignancies from benign conditions with high sensitivity and specificity.
2. Neurodegenerative Diseases & Central Nervous System (CNS) Disorders
The human brain exhibits the highest diversity of lncRNA expression compared to any other organ. These non-coding transcripts play essential roles in synaptic plasticity, neuronal differentiation, and epigenetic regulation. Dysregulation of specific lncRNAs has been implicated in Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). Implementing lncRNA-Seq in CNS disease models helps map the regulatory networks controlling neuroinflammation and protein aggregation, opening up novel pathways for RNA-targeted small molecules and antisense therapies.
3. Agricultural Biotechnology & Crop Resilience
Beyond human health, lncRNA-Seq is a powerful tool in agricultural genomics (AgBio). Plants rely heavily on non-coding RNAs to coordinate responses to environmental stresses, including drought, salinity, and pathogen attacks. By profiling lncRNAs in climate-resilient crop cultivars, agricultural researchers can identify key non-coding regulators that control stress-responsive genes. These discoveries guide marker-assisted selection and gene-editing programs designed to engineer crops with higher yields and improved resilience to climate change.
4. Host-Pathogen Interactions & Metagenomics
During infection, both host cells and pathogens undergo rapid transcriptional changes. Host lncRNAs have been shown to modulate innate immune responses and inflammatory pathways. By combining lncRNA-Seq with metagenomic profiling, researchers can study how host regulatory pathways respond to bacterial, viral, or fungal invasions. This dual profiling approach provides a comprehensive view of host-pathogen dynamics, driving the development of immunotherapies and host-directed antimicrobial strategies.
Strategic Product Positioning for Research & Development
Whether you are designing a clinical trial, developing a crop strain, or mapping basic cellular biology, incorporating lncRNA-Seq into your experimental design ensures that you do not miss the regulatory checkpoints of the genome. Standard mRNA sequencing captures only the downstream effectors; lncRNA sequencing reveals the upstream controllers, providing a complete biological picture.
Enterprise Qualifications & Intellectual Property
Demonstrated operational excellence and IP leadership backed by global standards and national certifications.
Joint Laboratories & Academic Workstations
Quality Standards & Patent Certifications
Comprehensive Multi-Omics Product Catalog
Discover our full suite of sequencing, extraction, and bioinformatic solutions tailored for global science initiatives.
DNBSEQ Pre-made Libraries for lncRNA Discovery
Cost-efficient, high-fidelity library preparations structured to streamline large-scale transcriptomic screening campaigns.
Learn More →
circ-RNA & lncRNA Multi-Omics Profiling
Advanced profiling protocols designed to map circular and long non-coding RNA networks with single-nucleotide precision.
Learn More →
TGuide Smart Soil / Stool RNA & DNA Kit
Automated extraction kits optimized for complex environmental and microbiome samples, preserving fragile non-coding RNA structures.
Learn More →
Bioinformatic Toolkits for non-coding RNA
Preconfigured analytical pipelines designed to fast-track the identification, annotation, and target prediction of novel transcript structures.
Learn More →
Microbial Genome Re-Sequencing for Host-lncRNA Studies
Complete bacterial and fungal sequencing setups designed to explore genomic variations and correlate them with host regulatory events.
Learn More →
High-Throughput Proteomics & lncRNA Correlation
Quantitative mass spectrometry solutions linked with transcriptomic pipelines to validate translations and downstream signaling pathways.
Learn More →
TGuide Smart Universal RNA & DNA Kit
A versatile, magnetic-bead-based automated extraction kit optimized for high-purity nucleic acid recovery from diverse biological matrices.
Learn More →
ATAC-seq for Chromatin Accessibility & lncRNA Binding
Epigenomic maps showing open chromatin regions, transcription factor binding dynamics, and active non-coding transcription loci.
Learn More →Accelerate Your Transcriptomics Project Today
For inquiries about our sequencing platforms, product specifications, or project pricelists, please connect with our team. We will be in touch within 24 hours.
Inquiry Now
